RECOMBINATE 1000 IU

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL

Disponível em:

TEVA MEDICAL MARKETING LTD.

Código ATC:

B02BD02

Forma farmacêutica:

POWDER FOR SOLUTION FOR INJECTION

Via de administração:

I.V

Fabricado por:

BAXTER S.A., BELGIUM

Grupo terapêutico:

COAGULATION FACTOR VIII

Indicações terapêuticas:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Data de autorização:

2010-07-01